Casdin Capital Reduces Stake in BioLife Solutions

Casdin Capital, LLC, along with its affiliates, has filed an amendment to its Schedule 13D, reporting a reduction in its stake in BioLife Solutions, Inc. As of October 17, 2025, Casdin Capital and its related entities collectively own 5,957,165 shares, representing 12.4% of the outstanding shares. This marks a decrease of 1,750,000 shares from their previous holdings. The shares were acquired for investment purposes, and the Reporting Persons reserve the right to engage in further transactions or discussions with the company's management and other shareholders to maximize shareholder value. The filing also includes a schedule of transactions, detailing the sale of 750,000 shares on October 15, 2025, at a price of $28.5471 per share.